NRResearcher profile · from public sources
Natasha Rekhtman
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation.
Science translational medicine, Nov 2026
Publication
Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.
Science (New York, N.Y.), Sept 2026
Publication
Peribronchial cuffing: an underrecognized pattern of prostate carcinoma metastases to the lung.
BJC reports, Jul 2026
Publication
Lung Carcinoids with Sustentacular Cells and Low Keratin Expression: A Common yet Underrecognized Phenomenon with Diagnostic and Biological Implications.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Jul 2026
Publication
Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jun 2026
Publication
Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.
Science translational medicine, Jun 2026
Publication
IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jun 2026
Publication
Early fibrotic niches establish tumour-permissive microenvironments.
Nature, Apr 2026
Publication
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.
Cell, Mar 2026
Publication
De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.
JAMA dermatology, Mar 2026
Publication
TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Feb 2026
Publication
Primary Pulmonary Ameloblastoma: First Case Series With Clinicopathologic and Genomic Analysis.
The American journal of surgical pathology, Jan 2026
Publication
Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Jan 2026
Publication
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours.
Histopathology, Jan 2026
Publication
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
JCO precision oncology, Nov 2025
Publication
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Clinical and translational medicine, May 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Reinhard Büttner directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error